Reply.
作者信息
Arase Yoshitaka, Kagawa Tatehiro
机构信息
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Division of Gastroenterology and Hepatology, Tokai University Oiso Hospital, Nakagun, Japan.
出版信息
Hepatology. 2020 Mar;71(3):1132-1133. doi: 10.1002/hep.30999. Epub 2020 Mar 4.
Abstract
摘要
相似文献
1
Reply.回复。
Hepatology. 2020 Mar;71(3):1132-1133. doi: 10.1002/hep.30999. Epub 2020 Mar 4.
2
Reply.回复。
Hepatology. 2020 Jul;72(1):360-361. doi: 10.1002/hep.31084.
3
Denosumab treatment in postmenopausal women with osteoporosis - Authors' reply.
Lancet Diabetes Endocrinol. 2017 Oct;5(10):768-769. doi: 10.1016/S2213-8587(17)30288-7.
4
Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity.
Hepatology. 2020 Mar;71(3):1131-1132. doi: 10.1002/hep.31001. Epub 2020 Mar 5.
5
Reply.回复。
Arthritis Rheumatol. 2019 Oct;71(10):1771-1772. doi: 10.1002/art.41013. Epub 2019 Sep 2.
6
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.骨质疏松症患者从双膦酸盐类药物转换为地诺单抗治疗过程中的颌骨骨坏死。
Odontology. 2018 Oct;106(4):469-480. doi: 10.1007/s10266-018-0362-5. Epub 2018 Apr 30.
7
One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.不同抗骨质疏松药物的一年和两年持续治疗情况：一项回顾性队列研究。
Osteoporos Int. 2017 Oct;28(10):2997-3004. doi: 10.1007/s00198-017-4144-7. Epub 2017 Jul 16.
8
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.绝经后骨质疏松症妇女使用地舒单抗 24 个月的持续治疗：一项前瞻性队列研究结果。
Arch Osteoporos. 2018 Aug 7;13(1):85. doi: 10.1007/s11657-018-0491-z.
9
The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.地舒单抗预防肺部疾病患者类固醇诱导性骨质疏松症的临床获益。
Arch Osteoporos. 2017 Dec;12(1):44. doi: 10.1007/s11657-017-0336-1. Epub 2017 Apr 19.
10
Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.地诺单抗治疗一名与原发性硬化性胆管炎相关的继发性骨质疏松症患者后出现严重低钙血症。
Endocr J. 2019 Mar 28;66(3):271-275. doi: 10.1507/endocrj.EJ18-0545. Epub 2019 Feb 2.
本文引用的文献
1
Review article: impact of exercise on physical frailty in patients with chronic liver disease.综述文章：运动对慢性肝病患者身体虚弱的影响。
Aliment Pharmacol Ther. 2019 Nov;50(9):988-1000. doi: 10.1111/apt.15491. Epub 2019 Sep 9.
2
Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.3年地诺单抗治疗自身免疫性肝病患者骨质疏松症的疗效与安全性
Hepatology. 2020 Feb;71(2):757-759. doi: 10.1002/hep.30904. Epub 2019 Oct 10.
3
Association between sarcopenia and osteoporosis in chronic liver disease.慢性肝病中肌肉减少症与骨质疏松症之间的关联。
Hepatol Res. 2018 Oct;48(11):893-904. doi: 10.1111/hepr.13192. Epub 2018 Jun 1.
4
Physical activity and liver diseases.体力活动与肝脏疾病。
Hepatology. 2016 Mar;63(3):1026-40. doi: 10.1002/hep.28132. Epub 2015 Dec 18.
5
Effects of physical activity on bone remodeling.体力活动对骨重建的影响。
Metabolism. 2011 Mar;60(3):373-88. doi: 10.1016/j.metabol.2010.03.001. Epub 2010 Mar 31.
Zotero 插件